<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798391</url>
  </required_header>
  <id_info>
    <org_study_id>CMHQ</org_study_id>
    <nct_id>NCT04798391</nct_id>
  </id_info>
  <brief_title>Effectiveness of Intratympanic Dexamethasone With Ligmocaine for Alleviation of Tinnitus</brief_title>
  <official_title>Effectiveness of Dexamethasone With Lignocaine for Alleviation of Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Combined Military Hospital, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Combined Military Hospital, Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine the effectiveness of Intratympanic dexamethasone with lignocaine in&#xD;
      control of idiopathic tinnitus.&#xD;
&#xD;
      Methodology: 264 consenting patients with idiopathic unilateral tinnitus presenting at ENT&#xD;
      Department were assessed for tinnitus severity using Modified Tinnitus Handicap Inventory and&#xD;
      the scores recorded and subsequently administered intratympanically 2.0 ml (milliliter's) of&#xD;
      dexamethasone and lignocaine (1.5 ml dexamethasone + 0.5 ml 1% lignocaine). The dose was&#xD;
      repeated twice at weekly intervals. All patients were re assessed on Modified Tinnitus&#xD;
      Handicap Inventory two weeks after third Intratympanic administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tinnitus relief</measure>
    <time_frame>2 weeks</time_frame>
    <description>Tinnitus relief ascertained by Modified Tinnitus Handicap Inventory</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>Dexamethasone with lignocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Steroids and analgesics</description>
    <arm_group_label>Dexamethasone with lignocaine</arm_group_label>
    <other_name>Lignocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  score 20 or above on modified tinnitus handicap inventory&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  head trauma, tympanic membrane perforation, depression, ear surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Combined Military Hospital</name>
      <address>
        <city>Quetta</city>
        <state>Balochistan</state>
        <zip>1234</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Combined Military Hospital, Pakistan</investigator_affiliation>
    <investigator_full_name>FARAH AFZAL</investigator_full_name>
    <investigator_title>CLASSIFIED SPECIALIST</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

